Pharmaceuticals News and Research

RSS

PCMA releases statement on President Obama's budget proposal for biotech medications

Pharmaceutical Care Management Association President and CEO Mark Merritt released the following statement on President Obama's budget proposal that would grant brand-name drug manufacturers seven years of market exclusivity before generic versions of biologic products can enter the market, instead of the 12 years that was passed in the health reform bill.

15 Feb 2011

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

Apricus Biosciences, Inc., announced today that it has entered into a licensing agreement granting Neopharm Group the exclusive rights to market and sell Vitaros®, Apricus Bio's treatment for erectile dysfunction ("ED") and, when and if available, its formulation for the treatment of premature ejaculation ("PE"), in Israel and the Palestinian Territories of the Gaza Strip and the West Bank.

15 Feb 2011

New study: Poor pharmaceutical communication with Hispanic patients affect quality of care

A new study revealed that poor communication with Hispanic patients is adversely affecting the quality of care to this country's largest minority group. The Jeffrey Group, the largest independent communications agency targeting Latin audiences, and KCI Partners, a strategic market research and consulting firm, announced today the results of this study measuring the knowledge and perceptions of minority patients relating to healthcare issues.

15 Feb 2011

Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it received the interim report of its phase 2-3 trial to treat Alpha-1 deficiency with its flag product, Alpha-Antitrypsin, delivered by inhalation.

14 Feb 2011

K-V Pharmaceutical to raise $32 million through private placement

K-V Pharmaceutical Company today announced that it has entered into a definitive agreement with a group of institutional investors to raise approximately $32 million of gross proceeds from a private placement of 9,950,000 shares of its Class A Common Stock at $3.25 per share.

14 Feb 2011

Affymetrix introduces NG Class Detergents to advance study of integral membrane proteins

Affymetrix, Inc. today launched its Anatrace® brand Neopentyl Glycol (NG) Class™ Detergents, the next generation of detergents to significantly advance the study of integral membrane proteins (IMPs), the most important proteins found in the human genome.

14 Feb 2011

Chimerix announces completion of $45 million Series F financing

Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.

14 Feb 2011

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the second quarter of Fiscal Year 2011.

14 Feb 2011

BioTime to merge Glycosan with OrthoCyte

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.

14 Feb 2011

Questcor's pricing issue

After Questcor Pharmaceuticals raised the price of the drug Acthar, its sole product, more than 10-fold in 2007, its shares began a climb from pennies to $14 and change. Acthar

14 Feb 2011

Best Practices publishes new report on 'Innovations in Patient-Focused Initiatives'

For the biopharmaceutical industry, the changing healthcare marketplace has increased the importance - and difficulty - of interacting with patients to improve outcomes. New technologies and access restrictions have created both opportunities and challenges for approaching and engaging patient populations to improve disease control.

14 Feb 2011

Bohai second quarter net revenues increase 32% to $22.2 million

Bohai Pharmaceuticals Group, Inc., a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today reported record financial results for its second quarter of fiscal 2011 ended December 31, 2010.

14 Feb 2011

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.

14 Feb 2011

First Edition: February 14, 2011

Today's headlines are focused on President Obama's budget proposal and what it does and does not include.

14 Feb 2011

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

AVEO Pharmaceuticals, Inc. today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Fla.

14 Feb 2011

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

Napo Pharmaceuticals, Inc. is pleased to announce the positive results of a successfully completed Phase 2 study of crofelemer for the treatment of hospitalized adult patients with mild to moderate acute watery diarrhea conducted by its partner Glenmark Pharmaceuticals Ltd..

14 Feb 2011

FDA accepts King's ACUROX NDA for filing with Priority review classification

Acura Pharmaceuticals, Inc. today announced that it has been informed by King Pharmaceuticals Research and Development Inc. (King) that King's New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets was accepted for filing by the US Food and Drug Administration (FDA) with a Priority review classification and a Prescription Drug User Fee Act (PDUFA) date of June 17, 2011.

14 Feb 2011

Pharmaceuticals News and Research

PCMA releases statement on President Obama's budget proposal for biotech medications

Apricus Bio awards Neopharm exclusive rights to market and sell Vitaros in Israel and Palestinian Territories

New study: Poor pharmaceutical communication with Hispanic patients affect quality of care

Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

K-V Pharmaceutical to raise $32 million through private placement

Affymetrix introduces NG Class Detergents to advance study of integral membrane proteins

Chimerix announces completion of $45 million Series F financing

Tianyin Pharmaceutical's second quarter revenue increases 69.6% to $25.3 million

BioTime to merge Glycosan with OrthoCyte

Questcor's pricing issue

Best Practices publishes new report on 'Innovations in Patient-Focused Initiatives'

Bohai second quarter net revenues increase 32% to $22.2 million

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

First Edition: February 14, 2011

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

FDA accepts King's ACUROX NDA for filing with Priority review classification

Elite third quarter consolidated revenues increase 34% to $1.2 million

Less than one-third of acute stroke patients receive clot-busting drug within 60 minutes of hospital arrival

SynthRx to become wholly-owned subsidiary of ADVENTRX

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence